319 related articles for article (PubMed ID: 35503226)
1. Targeting SHP2 phosphatase in hematological malignancies.
Kanumuri R; Kumar Pasupuleti S; Burns SS; Ramdas B; Kapur R
Expert Opin Ther Targets; 2022 Apr; 26(4):319-332. PubMed ID: 35503226
[TBL] [Abstract][Full Text] [Related]
2. Tyrosine phosphatase
Chen X; Keller SJ; Hafner P; Alrawashdeh AY; Avery TY; Norona J; Zhou J; Ruess DA
Front Immunol; 2024; 15():1340726. PubMed ID: 38504984
[TBL] [Abstract][Full Text] [Related]
3. Double-edged roles of protein tyrosine phosphatase SHP2 in cancer and its inhibitors in clinical trials.
Song Y; Zhao M; Zhang H; Yu B
Pharmacol Ther; 2022 Feb; 230():107966. PubMed ID: 34403682
[TBL] [Abstract][Full Text] [Related]
4. Medicinal chemistry strategies for the development of protein tyrosine phosphatase SHP2 inhibitors and PROTAC degraders.
Tang K; Jia YN; Yu B; Liu HM
Eur J Med Chem; 2020 Oct; 204():112657. PubMed ID: 32738411
[TBL] [Abstract][Full Text] [Related]
5. Structure, function, and pathogenesis of SHP2 in developmental disorders and tumorigenesis.
Huang WQ; Lin Q; Zhuang X; Cai LL; Ruan RS; Lu ZX; Tzeng CM
Curr Cancer Drug Targets; 2014; 14(6):567-88. PubMed ID: 25039348
[TBL] [Abstract][Full Text] [Related]
6. Targeting protein tyrosine phosphatase SHP2 for the treatment of PTPN11-associated malignancies.
Yu B; Liu W; Yu WM; Loh ML; Alter S; Guvench O; Mackerell AD; Tang LD; Qu CK
Mol Cancer Ther; 2013 Sep; 12(9):1738-48. PubMed ID: 23825065
[TBL] [Abstract][Full Text] [Related]
7. A cellular target engagement assay for the characterization of SHP2 (PTPN11) phosphatase inhibitors.
Romero C; Lambert LJ; Sheffler DJ; De Backer LJS; Raveendra-Panickar D; Celeridad M; Grotegut S; Rodiles S; Holleran J; Sergienko E; Pasquale EB; Cosford NDP; Tautz L
J Biol Chem; 2020 Feb; 295(9):2601-2613. PubMed ID: 31953320
[TBL] [Abstract][Full Text] [Related]
8. SHP2 sails from physiology to pathology.
Tajan M; de Rocca Serra A; Valet P; Edouard T; Yart A
Eur J Med Genet; 2015 Oct; 58(10):509-25. PubMed ID: 26341048
[TBL] [Abstract][Full Text] [Related]
9. [The Biological Function of SHP2 in Human Disease].
Li SM
Mol Biol (Mosk); 2016; 50(1):27-33. PubMed ID: 27028808
[TBL] [Abstract][Full Text] [Related]
10. Allosteric inhibition of SHP2 phosphatase inhibits cancers driven by receptor tyrosine kinases.
Chen YN; LaMarche MJ; Chan HM; Fekkes P; Garcia-Fortanet J; Acker MG; Antonakos B; Chen CH; Chen Z; Cooke VG; Dobson JR; Deng Z; Fei F; Firestone B; Fodor M; Fridrich C; Gao H; Grunenfelder D; Hao HX; Jacob J; Ho S; Hsiao K; Kang ZB; Karki R; Kato M; Larrow J; La Bonte LR; Lenoir F; Liu G; Liu S; Majumdar D; Meyer MJ; Palermo M; Perez L; Pu M; Price E; Quinn C; Shakya S; Shultz MD; Slisz J; Venkatesan K; Wang P; Warmuth M; Williams S; Yang G; Yuan J; Zhang JH; Zhu P; Ramsey T; Keen NJ; Sellers WR; Stams T; Fortin PD
Nature; 2016 Jul; 535(7610):148-52. PubMed ID: 27362227
[TBL] [Abstract][Full Text] [Related]
11. Inflammatory response in hematopoietic stem and progenitor cells triggered by activating SHP2 mutations evokes blood defects.
Solman M; Blokzijl-Franke S; Piques F; Yan C; Yang Q; Strullu M; Kamel SM; Ak P; Bakkers J; Langenau DM; Cavé H; den Hertog J
Elife; 2022 May; 11():. PubMed ID: 35535491
[TBL] [Abstract][Full Text] [Related]
12. Allosteric Inhibitors of SHP2: An Updated Patent Review (2015-2020).
Wu J; Zhang H; Zhao G; Wang R
Curr Med Chem; 2021; 28(19):3825-3842. PubMed ID: 32988341
[TBL] [Abstract][Full Text] [Related]
13. Noonan syndrome-associated SHP2/PTPN11 mutants cause EGF-dependent prolonged GAB1 binding and sustained ERK2/MAPK1 activation.
Fragale A; Tartaglia M; Wu J; Gelb BD
Hum Mutat; 2004 Mar; 23(3):267-77. PubMed ID: 14974085
[TBL] [Abstract][Full Text] [Related]
14. Inhibition of SHP2 as an approach to block RAS-driven cancers.
Chou YT; Bivona TG
Adv Cancer Res; 2022; 153():205-236. PubMed ID: 35101231
[TBL] [Abstract][Full Text] [Related]
15. Gain-of-function mutations of Ptpn11 (Shp2) cause aberrant mitosis and increase susceptibility to DNA damage-induced malignancies.
Liu X; Zheng H; Li X; Wang S; Meyerson HJ; Yang W; Neel BG; Qu CK
Proc Natl Acad Sci U S A; 2016 Jan; 113(4):984-9. PubMed ID: 26755576
[TBL] [Abstract][Full Text] [Related]
16. The tyrosine phosphatase Shp2 in development and cancer.
Grossmann KS; Rosário M; Birchmeier C; Birchmeier W
Adv Cancer Res; 2010; 106():53-89. PubMed ID: 20399956
[TBL] [Abstract][Full Text] [Related]
17. Determination of the catalytic activity of LEOPARD syndrome-associated SHP2 mutants toward parafibromin, a bona fide SHP2 substrate involved in Wnt signaling.
Noda S; Takahashi A; Hayashi T; Tanuma S; Hatakeyama M
Biochem Biophys Res Commun; 2016 Jan; 469(4):1133-9. PubMed ID: 26742426
[TBL] [Abstract][Full Text] [Related]
18. Protein Tyrosine Phosphatase Non-Receptor 11 (
Richards CE; Elamin YY; Carr A; Gately K; Rafee S; Cremona M; Hanrahan E; Smyth R; Ryan D; Morgan RK; Kennedy S; Hudson L; Fay J; O'Byrne K; Hennessy BT; Toomey S
Int J Mol Sci; 2023 Jun; 24(13):. PubMed ID: 37445722
[No Abstract] [Full Text] [Related]
19. Functions of Shp2 in cancer.
Zhang J; Zhang F; Niu R
J Cell Mol Med; 2015 Sep; 19(9):2075-83. PubMed ID: 26088100
[TBL] [Abstract][Full Text] [Related]
20. Therapeutic potential of targeting SHP2 in human developmental disorders and cancers.
Shen D; Chen W; Zhu J; Wu G; Shen R; Xi M; Sun H
Eur J Med Chem; 2020 Mar; 190():112117. PubMed ID: 32061959
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]